Cover Image

High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitte...

Full description

Saved in:
Bibliographic Details
Main Authors: Weber, Tobias (Author) , Mier, Walter (Author) , Sauter, Max (Author) , Krämer, Susanne (Author) , Jäger, Dirk (Author) , Haberkorn, Uwe (Author) , Krauß, Jürgen (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: European journal of nuclear medicine and molecular imaging
Year: 2015, Volume: 43, Issue: 3, Pages: 489-498
ISSN:1619-7089
DOI:10.1007/s00259-015-3175-6
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-015-3175-6
Get full text
Author Notes:Tobias Weber, Benedikt Bötticher, Walter Mier, Max Sauter, Susanne Krämer, Karin Leotta, Armin Keller, Anne Schlegelmilch, Ludger Grosse-Hovest, Dirk Jäger, Uwe Haberkorn, Michaela A.E. Arndt, Jürgen Krauss
Description
Summary:Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter 177Lu. Both RICs were evaluated as single agents in a human Burkitt’s lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored.
Item Description:Published online: 04 September 2015
Im Titel ist die Zahl "177" hochgestellt
Gesehen am 18.05.2020
Physical Description:Online Resource
ISSN:1619-7089
DOI:10.1007/s00259-015-3175-6

Similar Items